ProKidney Corp.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $893.0K | $76.0K | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $114.1M | $127.7M | $106.7M | $82.1M |
| SG&A Expense | $51.8M | $56.1M | $44.8M | $70.9M |
| Operating Income | $-165.0M | $-183.7M | $-151.5M | $-153.0M |
| Operating Margin | -18,477.8% | -241,678.9% | — | — |
| Interest Expense | $4.0K | $9.0K | $12.0K | $215.0K |
| Pretax Income | $-151.2M | $-163.9M | $-129.5M | $-147.2M |
| Income Tax Expense | $414.0K | $-598.0K | $6.0M | $896.0K |
| Net Income | $-69.0M | $-61.2M | $-35.5M | $-148.1M |
| Net Margin | -7,725.2% | -80,507.9% | — | — |
| EPS (Basic) | — | — | — | $-0.23 |
| EPS (Diluted) | — | — | — | $-0.23 |
| Shares Outstanding (Basic) | — | — | — | 61.5M |
| Shares Outstanding (Diluted) | — | — | — | 61.5M |
| Dividends Per Share | — | — | — | — |